NEW YORK (GenomeWeb) – Cofactor Genomics announced today that it has partnered with the National Cancer Institute (NCI), in addition to agreements with three other unnamed academic and pharma groups, to demonstrate the clinical utility of Cofactor's RNA-based immune-profiling assay, Cofactor Paragon.

Under the terms of their material transfer agreement, the collaborators will use clinical specimens from several of NCI's clinical trials to validate the Paragon assay.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.